Related Experiment Video
Updated: Jun 19, 2026

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of
Laure Elens1, Jean-Cyr Yombi, Dominique Lison
1Louvain Center for Toxicology and Applied Pharmacology (LTAP), Université Catholique de Louvain, 53.02 Avenue E. Mounier, 1200 Bruxelles, Belgium. laure.elens@uclouvain.be
Aim:
Lopinavir (LPV) is a potent protease inhibitor used in combination with low doses of ritonavir in the treatment of HIV-infected patients. LPV pharmacokinetics is characterized by a large interindividual variability requiring the use of therapeutic drug monitoring in different clinical situations. While the sources of this variability are still unknown, several genetic polymorphisms in biotransformation enzymes or transporter proteins involved in the metabolism and/or the distribution of LPV appear as good candidates. Therefore, the aim of the present study was to investigate the influence of selected genetic polymorphisms on LPV trough plasma concentrations ([LPV](Cmin)), LPV concentrations in peripheral blood mononuclear cells ([LPV](CC)) and the LPV accumulation ratio ([LPV](CC):[LPV](Cmin)).
Materials & Methods:
A total of 53 patients receiving Kaletra((R)) (Abbott Laboratories, IL, USA) (LPV+ritonavir) were genotyped for 14 different polymorphisms in biotransformation enzymes and transporter proteins. [LPV](Cmin), [LPV](CC) and [LPV](CC):[LPV](Cmin) were compared according to the patient's genotypes.
Results & Conclusion:
The 4544G>A (rs8187710)polymorphism in ABCC2 was associated with a higher accumulation of LPV in peripheral blood mononuclear cells of HIV-treated patients. As already observed in previous studies, ABCB1 or CYP3A5 polymorphisms had no impact on [LPV](Cmin) and we did not detect any influence of these polymorphisms on [LPV](CC) and its accumulation in mononuclear cells. In conclusion, this pilot study suggests, for the first time, that the 4544G>A polymorphism in ABCC2 could explain a significant part of the interindividual variability in LPV pharmacokinetics. Further investigations are needed to confirm this association and to explore its real pharmacodynamic impact.
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
ABC Transporters: Importer
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Principles of Pharmacogenetics: Types of Genetic Variants
